Tübinger evaluation of Risk factors for Early detection of NeuroDegeneratio
- Conditions
- G20G30Parkinson diseaseAlzheimer disease
- Registration Number
- DRKS00022058
- Lead Sponsor
- niversitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1201
Ability to give consent and a written declaration of consent, depression cohort: Depressive episode or dysthymia (currently BDI <25 and CES-D <12 or in the last 10 years) according to the criteria of ICD 10 or DSM IV. REM sleep disorder cohort: Presence of the minimum requirements for diagnosis (1. Movement of the legs or body associated with dream activity, and 2. one of the following 3 criteria: (potentially) dangerous sleep behavior, living out dreams”, interruption of sleep continuity) (ICSD, 2001 ): Testing by questionnaire. Cohort with idiopathic disturbance of smell perception: history of reduced smell perception in the past years, pathological smell test. Cohort of symptom-free subjects: All three symptoms are excluded both by taking a medical history and by the tests mentioned above.
Any impairment that prevents the test person from giving his or her independent consent. Other diseases that make it impossible for the study participant to perform the necessary tasks within the scope of the study or to communicate with the study doctor. Classic neuroleptics or valproate have been taken in the last 3 months or a history of taking over 3 months. History of addiction. Benzodiazepam intake of more than the equivalent dose of 1.5 mg lorazepam. Cognitive deficits that cannot be explained by the existing symptoms (e.g. depression). Dementia, immobility (care level> 1), concrete move plans in the region outside of Baden-Württemberg.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method